MX2020000005A - Pirrolopirimidina que inhibe cinasa 1 reguladora de la se?al de apoptosis (ask1) y derivados de pirrolopiridina. - Google Patents

Pirrolopirimidina que inhibe cinasa 1 reguladora de la se?al de apoptosis (ask1) y derivados de pirrolopiridina.

Info

Publication number
MX2020000005A
MX2020000005A MX2020000005A MX2020000005A MX2020000005A MX 2020000005 A MX2020000005 A MX 2020000005A MX 2020000005 A MX2020000005 A MX 2020000005A MX 2020000005 A MX2020000005 A MX 2020000005A MX 2020000005 A MX2020000005 A MX 2020000005A
Authority
MX
Mexico
Prior art keywords
diseases
pyrrolopyrimidine
present
pyrrolopyridine derivatives
ask1
Prior art date
Application number
MX2020000005A
Other languages
English (en)
Inventor
Gordon Saxty
Karl Richard Gibson
David Amantini
Milan Mesic
Tanja Poljak
Ines Vujasinovic
Dinko Ziher
David Witty
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MX2020000005A publication Critical patent/MX2020000005A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención está relacionada con compuestos de pirrolopirimidina de acuerdo con la Fórmula I y su uso en la profilaxis y/o el tratamiento del dolor, afecciones inflamatorias, enfermedades cardiovasculares, enfermedades neurodegenerativas, enfermedades neurológicas, complicaciones de la diabetes tipo I, el cáncer y/o enfermedades fibróticas. En un aspecto particular, los compuestos de la presente son inhibidores de ASK (cinasa 1 reguladora de la señal de apoptosis, por sus siglas en inglés). La presente invención también proporciona métodos para la producción de un compuesto de la invención, composiciones farmacéuticas que comprenden un compuesto de la invención, el uso de los compuestos en la profilaxis y/o el tratamiento del dolor, de afecciones inflamatorias, enfermedades cardiovasculares, enfermedades neurodegenerativas, enfermedades neurológicas, complicaciones de la diabetes tipo I, el cáncer y/o enfermedades fibróticas. (ver Fórmula).
MX2020000005A 2017-07-12 2018-07-12 Pirrolopirimidina que inhibe cinasa 1 reguladora de la se?al de apoptosis (ask1) y derivados de pirrolopiridina. MX2020000005A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1711234.3A GB201711234D0 (en) 2017-07-12 2017-07-12 Pyrrolopyrimidine and pyrrolopyridine derivatives
PCT/GB2018/051983 WO2019012284A1 (en) 2017-07-12 2018-07-12 PYRROLOPYRIMIDINE AND ASK1 INHIBITING PYRROLOPYRIDINE DERIVATIVES

Publications (1)

Publication Number Publication Date
MX2020000005A true MX2020000005A (es) 2020-08-06

Family

ID=59676761

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000005A MX2020000005A (es) 2017-07-12 2018-07-12 Pirrolopirimidina que inhibe cinasa 1 reguladora de la se?al de apoptosis (ask1) y derivados de pirrolopiridina.

Country Status (18)

Country Link
US (2) US11136325B2 (es)
EP (1) EP3652173A1 (es)
JP (1) JP7198263B2 (es)
KR (1) KR20200028436A (es)
CN (1) CN111094283A (es)
AR (1) AR112333A1 (es)
AU (1) AU2018300218B2 (es)
BR (1) BR112020000578A2 (es)
CA (1) CA3069358A1 (es)
CO (1) CO2020001346A2 (es)
GB (1) GB201711234D0 (es)
IL (1) IL271910B2 (es)
MX (1) MX2020000005A (es)
PH (1) PH12019502823A1 (es)
SG (1) SG11202000168UA (es)
TW (1) TWI794253B (es)
UY (1) UY37809A (es)
WO (1) WO2019012284A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201711234D0 (en) * 2017-07-12 2017-08-23 Galapagos Nv Pyrrolopyrimidine and pyrrolopyridine derivatives
CN111303155A (zh) * 2020-03-13 2020-06-19 深圳大学 靶向pak1抑制剂及其在抗肿瘤治疗药物中的应用
CN111704617B (zh) * 2020-06-15 2022-08-23 嘉兴特科罗生物科技有限公司 一种小分子化合物
KR102635126B1 (ko) * 2021-05-27 2024-02-13 한국과학기술연구원 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 피롤로피리미딘 유도체 및 이들의 용도
AR126584A1 (es) * 2021-07-28 2023-10-25 Epirium Bio Inc Inhibidores de pgdh de pirrolo[2,3-b]piridina y métodos para hacerlos y usarlos
KR20230019801A (ko) * 2021-08-02 2023-02-09 한국화학연구원 신규한 피롤로 피리미딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 대사성 간질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU784878B2 (en) 1999-12-02 2006-07-13 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 A2A and A3 receptors and uses thereof
TW200306191A (en) * 2002-02-22 2003-11-16 Teijin Ltd Pyrrolopyrimidine derivatives
US7390625B2 (en) 2002-11-22 2008-06-24 Takeda Pharmaceutical Company Limited Apoptosis-associated protein and use thereof
EP2058309A4 (en) 2006-08-04 2010-12-22 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
CA2672373C (en) 2006-12-19 2011-08-30 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
KR20100075881A (ko) 2007-08-31 2010-07-05 메르크 세로노 에스. 에이. 트리아졸로피리딘 화합물 및 ａｓｋ 저해제로서 이의 용도
EP2271646A1 (en) 2008-03-31 2011-01-12 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
TWI491606B (zh) * 2009-07-13 2015-07-11 Gilead Sciences Inc 調節細胞凋亡信號之激酶的抑制劑
US9045485B2 (en) * 2010-12-16 2015-06-02 Convergence Pharmaceuticals Limited ASK 1 inhibiting pyrrolopyrimidine derivatives
GB201711234D0 (en) * 2017-07-12 2017-08-23 Galapagos Nv Pyrrolopyrimidine and pyrrolopyridine derivatives

Also Published As

Publication number Publication date
US11136325B2 (en) 2021-10-05
CN111094283A (zh) 2020-05-01
IL271910B1 (en) 2023-03-01
WO2019012284A1 (en) 2019-01-17
JP2020530833A (ja) 2020-10-29
US20220169653A1 (en) 2022-06-02
PH12019502823A1 (en) 2020-10-26
EP3652173A1 (en) 2020-05-20
GB201711234D0 (en) 2017-08-23
CA3069358A1 (en) 2019-01-17
AU2018300218B2 (en) 2021-12-16
BR112020000578A2 (pt) 2020-07-14
UY37809A (es) 2019-02-28
IL271910A (en) 2020-02-27
AR112333A1 (es) 2019-10-16
IL271910B2 (en) 2023-07-01
AU2018300218A1 (en) 2020-02-27
RU2020106289A (ru) 2021-08-12
TW201908312A (zh) 2019-03-01
US20200165259A1 (en) 2020-05-28
TWI794253B (zh) 2023-03-01
KR20200028436A (ko) 2020-03-16
JP7198263B2 (ja) 2022-12-28
SG11202000168UA (en) 2020-02-27
RU2020106289A3 (es) 2021-11-10
CO2020001346A2 (es) 2020-05-29

Similar Documents

Publication Publication Date Title
PH12019502823A1 (en) Pyrrolopyrimidine and pyrrolopyridine derivatives
NZ738187A (en) Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
PH12019500480A1 (en) Pyridine compound
PH12019500214A1 (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
WO2016118951A3 (en) Heterocyclic itk inhibitors for treating inflammation and cancer
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
WO2019152419A8 (en) Prc2 inhibitors
EA033237B1 (ru) Новые производные пиразолопиримидина в качестве ингибиторов nik, фармацевтическая композиция и лекарственное средство, содержащее ее
PH12017500007A1 (en) Quinolizinone derivatives as p13k inhibitors
MX2017003466A (es) Inhibidores de histona desmetilasa.
IN2015MN00002A (es)
PH12020550442A1 (en) Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
PH12018500827A1 (en) 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors
SG10201907291QA (en) Monomethylfumarate prodrug compositions
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2021010093A (es) Derivados de pirazolopiridina como inhibidores serina/treonina cinasa que contiene el dominio per-arnt-sim (pask).
MX2019014438A (es) Derivados de acidos carboxilicos eficaces como inhibidores de la proteina quinasa.
MX2019014436A (es) Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa.
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
MX2020013608A (es) Preparacion de derivados de triazepina condensados y su uso como inhibidores de bet.